Content
June 2002, Volume 3, Issue 2
- 137-138 Time for a change in drug licensing requirements?
by Michael F. Drummond - 138-138 Commentary
by J.-Matthias Graf Schulenburg - 139-139 Commentary
by Bengt Jönsson - 140-141 Time for a change in drug pricing : Going downstream
by Gérard Pouvourville - 141-142 Drug licensing requirements are changing!
by F. Lekkerkerker & F. Rutten - 142-142 A final comment
by Michael F. Drummond
March 2002, Volume 3, Issue 1
- 3-9 Costing hospital activity: the experience with healthcare resource groups in England
by A. Street & D. Dawson - 10-16 Comparing the results of applying different methods of eliciting time preferences for health
by Dorte Gyrd-Hansen - 17-25 Devolved budgetary responsibility in primary care
by P. Wilton & R. D. Smith - 26-39 Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction
by K. M. Antioch & G. Jennings & M. Botti & R. Chapman & V. Wulfsohn - 40-46 Priorities and Prospect Theory
by M. Happich & B. Mazurek - 47-53 Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies
by J. F. P. Bridges & M. Stewart & M. T. King & K. van Gool - 54-58 Does health technology assessment benefit health services and politics?
by H. Sigmund & F. B. Kristensen - 59-65 Overview of economic evaluation of positron-emission tomography
by A. Müller & D. Stratmann-Schöne & T. Klose & R. Leidl - 66-70 Pricing and reimbursement of drugs in Sweden
by J. Lundkvist - 71-71 Report on the 4 th ISPOR European Annual Meeting in November 2001 in Cannes, France
by Wolfgang Greiner